Skip to main content

Table 3 Effects of drug interactions between components of different combinations

From: Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: A tangible union against chemoresistant cancer

Modalities Cell Line Combination Index (CI1) Drug Alone
(×IC50)
Dose Reduction Index (×IC50) R3 Effect4
   IC2 50 PNP Doc Car PNP Doc Car   
Docetaxel
Carboplatin
SKOV5 0.96 - 5.01 1.34 - 2.7 1.68 0.98 Additive
+
  OVCAR6 0.89 - 2.76 2.16 - 2.1 2.44 0.99 Additive
+
PNP-GDEPT
Docetaxel
SKOV 0.43 8.22 5.01 - 6.12 3.7 - 0.98 Synergy
+++
  OVCAR 0.21 2.03 2.76 - 7.97 10.82 - 0.93 Strong Synergy
++++
PNP-GDEPT
Carboplatin
SKOV 0.29 8.22 - 1.34 12.36 - 4.7 0.97 Strong Synergy
++++
  OVCAR 0.28 2.03 - 2.16 5.66 - 9.08 0.96 Strong Synergy
++++
GDEPT Docetaxel
Carboplatin
SKOV 0.37 8.22 5.01 1.34 13.96 8.51 5.3 0.96 Strong Synergy
++++
  OVCAR 0.11 2.03 2.76 2.16 19.89 27.02 31.9 0.94 Very Strong Synergy
+++++
  1. 1 Combination index values generated when drugs were combined at constant ratio of 1:1 e.g. IC25 of docetaxel with IC25 of carboplatin; 2ED, Effective dose, which can result in 50, 75 and 90% of cell killing; 3The linear correlation coefficient, R, of the median-effect plot. The acceptable range of 'R' values varies with the type of system used; Enzyme or receptor systems (r > 0.96), tissue culture systems (r > 0.90) and animal experiments (r > 0.85); 4Combination effects, CI value 0.90-1.10 signifies additivity (+); CI 0.7-0.85 moderate synergism (++); CI 0.85-0.9 slight synergies (+++); CI 0.30-0.70 synergism (++++); CI 0.10-0.30 strong synergism (+++++) and CI 0.01-010 very strong synergism (++++++); 5 represents SKOV-3; 6 represents OVCAR-3